Member Info for Romeike

Only because its SP was hugely over-pumped ahead of first gold pour and begging for correction. Such is the way with these easily manipulated stocks.

These small goldies are all about the people in charge. The rest barely matters. You can have an excellent gold facility in, let's say Turkey for example, and end up with it being worth barely anything due to the extraordinary incompetence of a bunch of old fools running the show. Emma Priestly and her team are top rank and meeting her briefly was enough to cause me to dump my entire Stratex holding and move it to Goldstone.

GRL - production starts 2 months, extended permit due within six months. Do your own research, but at least do it properly! Sorry to hear about the massive dilution here, same old story with this one though to be fair.

And to think the old fools at Stratex/ ORR sold their stake for a pittance when they were chasing nonsense plans in Brazil of all places after the absolute scandal in Turkey.

But it isn't ask if GSK is helpless in this, they have a whole fx team in finance to mitigate currency fluctuations over the long term, it's not like they immediately convert USD -> GBP at the most derisory rate available at any given time. Hard to believe this was 1850 not so long ago.

As a global leader in vaccines, GSK's partnership with Sanofi , and other partnerships with biotech partners like Vir, stand the best chance of an effective, safe vaccine manufactured at industrial scale based on proven technology . Why then is GSK well down YTD while others are up 5-35%? So much buzz about the experimental Oxford vaccine that vaccine giants wouldn;t touch. There's a reason why AZ, with zero vaccine experience, was left to partner with Oxford after no one else would touch it.

I would't necessarily underestimate Namibia either.

It would be good if they could monetise the gas, but at current prices it just isn't viable.

I guess because non-operated assets are often the first to go and they need to pay down debt fast so selling decent but non-core stuff is the way to meet their fund raising objectives.

Occidental's minority stake in both Jubilee (21kbpd) and TEN (8kbpd) iirc are up for sale again following Total's waiver. I guess Tullow must be looking at these given that it is the operator, but I have no idea how they would pay for it.

I agree production on Jubilee is now excellent. But production is TEN is a shameful disaster and remains an urgent issue that the new CEO must grapple with. They need an extensive work programme in 2021 to compensate for the crappy Enyenra wells and get that production back up towards 100kbpd where it actually constitutes a viable business.

What always bothered me about Dot's forward guidance, and believe me I have had almost tearful exchanges with IR folk on this matter, no joke, is that they were guiding for 150kbpd as recently as late 2018 and now they are talking about just 70kbpd while running at 76kbpd currently and still be guarded over the details of how much of the benefit of the 2020 work programme is included in this forecast. If I was not so depressed about the whole thing I honestly cannot help wondering if the police should 'avin words with McDade as you cannot simply dismiss this as "bad forecasting".

Do we know for a fact that Ntomme-9 is delayed? To date I have been told there has been no impact of activities in Ghana. What hasn't been made clear is if production from Ntomme-9 is factored into the c70kbpd forecast for 2021. In the absence of further information I have to assume it is. What makes little sense though is that with production running at 76kbpd and all the work programme activity this year, what underlies their assumption for the large 5kbpd decline to arrive at their 2021 forecast numbers?

AZN are doing well, why mess it up with an expensive acquisition only made possible by the recent increase in market cap? Gilead itself is very over priced right now makimg talk of buyout even less attractive. These huge corporate actions rarely benefit shareholders of the aquirer, just line bankers pockets and payouts for the board. Why not increase the dividend instead?

I agree. GSK are likely to capture significant market share in HIV.

Lol. Gileaf is not a great company and AZN is valuation is already really stretched. They need to consolidate the share price not exploit it on some buyout that only benefits executives.

Surely you mean sell on this rumour? Thisnews is actually bad for AZN. Buy Gilead perhaps.

Good time to pick up Truvada just as it's about to get a kicking courtesy of Viiv.

It's just rumour anyway, but not sure I understand folk thinking that paying a 30+% premium for finacially messy Gilead and it's outdated portfolio will be great for AZN. The board has been lucky to see AZN stock rally considerably in reason times. They should be looking to consolidate those gains but unfortunately seem to be falling down the usual route of ego boosting corporate actions regardless of benefits for shareholders. Smacks of a lack of ideas.

Jubiler is one of the lowest production fields in the world. The Permian Basin will be abandoned wasteland before Tullow is having to resort to its headroom to pay the bills.